LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by relevance 45 pages found matching Zetia- Demanda Colectiva por la Comercializacion Fraudulenta de Vytorin
Los fabricantes de la droga de colesterol Vytorin están bajo fuego por supuestamente hacer falsas reclamaciones en su campaña de marketing. El General Fiscal de Nueva York, Andrew Cuomo está investigando si la campaña de marketing de Vytorin viola de las leyes estatales relativas a la publicidad falsa. Specifically, offici... - Merck ERISA Lawsuit Filed
Jun-24-08 Hartford, CT A lawsuit has been filed against Merck alleging the company violated Employee Retirement Income Security Act (ERISA) laws in its managing of employee investments in Merck Plans. The lawsuit was filed June 20, 2008, in New Jersey. According Nancy Kulesa, an associate with Schatz Nobel Izard PC, the complaint against Merck relates to its... - Merck and ERISA: Did Vytorin Constitute a Violation?
Jun-16-08 Whitehouse Station, NJ Merck's role in the alleged delay of the ENHANCE study that ultimately revealed the truth about Vytorin, may have served to mislead more than the drug-buying public. The two-year wait for the truth about the anti-cholesterol drug may have also served to pull the wool over the eyes of those Merck employees, and investors in various M... - Possible Merck ERISA Violation Regarding Vytorin
Apr-29-08 Whitehouse Station, NJ When Merck dragged its feet for 21 months before releasing the ENHANCE study shaming Vytorin , the manufacturer allegedly did more than delay the bad news: it may have also delayed the returns, and derailed the retirement plans of thousands of investors unaware of a ticking time bomb. But Merck knew, and in so doing may have breac... - Avandia Maker Cited by the FDA
Apr-15-08 Washington, DC In what appears to be an epidemic amongst drug manufacturers, the US Food and Drug Administration (FDA) has taken Avandia maker GlaxoSmithKline to task for withholding information about the drug long suspected of harboring a higher risk of heart attack than patients on other diabetes drugs. A stern warning letter was forwarded to Glax... - Vytorin Kidney Failure: "It's going to end my life soon."
Mar-12-08 Plano, TX Three years ago, Jim Wiley was taking Lipitor, a statin drug, for elevated cholesterol and tolerating it well. That was when Merck/Schering-Plough introduced Vytorin , a combination drug that contained their proprietary anti-cholesterol drug Zetia and the statin drug Zocor (simvastatin). That's also when things took a turn for the worse&mdas... - Ezetrol: Canadian Version of Zetia Questioned
Mar-9-08 Toronto, ON As if the Zetia and Vytorin issue wasn't enough of a frustration on its own, north of the border in Canada the Canadian equivalent of Zetia— Ezetrol —is proving just as mystifying. At issue: does the cholesterol drug work? Is it harmful? And did the manufacturer, as it was accused of doing in the US, withhold important safety a... - Ayuda Legal Para Victimas de Ataque Cardiaco (Infarto) o Derrame Cerebral por Ezetrol
Merck y Shering-Plough han anunciado que, sobre la base de un estudio de 720 pacientes, Vytorin, que combina Zetia (Ezetimiba) y Zocor (simvastatina), no reduce el crecimiento de la placa arterial grasosa. Por lo contrario, los pacientes que tomaron Vytorin tenian más crecimiento de placa que los pacientes que tomaron este fármaco sólo. En Canadá, la dro... - Ezetrol: America's Problems are Canada's Problems... and You're Paying for Them
Feb-28-08 Ottawa, ON Nowadays, Canada's neighbors include the likes of pharmaceutical giants Merck/Schering Plough ; they also include the US federal Food and Drug Administration (FDA). Merck/Schering and its Canadian subsidiary Merck Frosst is the big pharma consortium that manufactures and sells Ezetrol (Zetia in the US market), the anti-cholesterol drug that i... - Ezetrol: Zetia by Any Other Name...
Feb-25-08 Toronto, ON Canadian visitors to LawyersAndSettlements may wonder about all the recent uproar around Zetia , Merck Pharmaceuticals' costly and quite possibly ineffective anti-cholesterol drug, and its offshoot Vytorin , the combination Zetia/simvastatin (Zocor) drug produced jointly by Merck/Schering-Plough. Vytorin, of course, was the subject of the rec... - Zetia: How Did It Get Here?
Feb-18-08 Washington, DC The emerging scandal surrounding Merck/Schering-Plough's Zetia and Vytorin cholesterol-lowering drugs has raised questions about some related issues. To recap: on January 14, after nearly a two-year delay, Merck/Schering released the results of its ENHANCE testing program for their combination Zetia/simvastatin (Zocor) drug called Vytori... - Zetia/Vytorin: Whose Word Can You Trust?
Feb-11-08 Washington, DC The long-delayed release of the ENHANCE testing results for Merck/Schering-Plough's Vytorin anti-cholesterol drug on January 14 brought on a storm of responses. The ENHANCE results indicated that Vytorin, which combines Merck/Schering's Zetia with generic simvastatin (Zocor), did lower patients' LDL (bad) cholesterol somewhat better than s... - Schering-Plough: Dragging Heels on Vytorin Study, a Breach of ERISA?
Feb-5-08 Kenilworth, NJ The long-awaited, and long-delayed release of the ENHANCE study on the effects and efficacy of the cholesterol drug Vytorin (Zocor combined with Zetia) may have done more than raise the ire of doctors and the medical community: it also may have ticked off investors of Schering-Plough , one of the two manufacturers involved in Vytorin. The... - Zetia/Vytorin: What Did They Know and When Did They Know It?
Feb-3-08 Kenilworth, NJ: The scandal over Merck/Schering-Plough's long delay in releasing the results of the ENHANCE tests of its big-bucks anti-cholesterol medication Vytorin continues to grow—to the extent that The Wall Street Journal now calls it "Vytoringate". And like its predecessor scandal, the focus of investigations has come down to a simple question: Wh... - Zetia Raises Heart Attack Risks
Feb-2-08 Whitehouse Station, NJ: The Food and Drug Administration (FDA) said, on Friday (Jan 25, 2008), that they will review the safety and efficacy of Zetia /Zocor (Vytorin) after results from the ENHANCE trial suggested that the combination had no significant reduction in atherosclerotic-plaque progression. Steven Nissen, M.D., director of cardiovascular med... - Zetia/Vytorin: "I can't afford to take any more chances."
Jan-30-08 Huntington Beach, CA: George Stavros fits the profile of someone who would be prescribed Merck/Schering-Plough's Zetia anti-cholesterol drug to help prevent a possible heart attack. The question is whether it did him more harm than good. Stavros (not his real name pending possible legal action) has a history of cardiovascular disease dating back to 19... - Zetia/Vytorin Manufacturers Pull TV Ads
Jan-24-08 Kenilworth, NJ: Merck/Schering-Plough announced on Tuesday January 22, that they are pulling all direct-to-consumer (DTC) television advertisements for their Zetia and Vytorin products. Zetia is Merck/Schering's branded anti-cholesterol drug which is also used in Vytorin, which contains Zetia and the statin drug Zocor (simvastation). Merck/Schering's... - Congressional Investigation and Class Action Lawsuit Target Zetia Manufacturers
Jan-23-08 Washington, DC: The House committee that has been investigating Merck/Schering-Plough's two-year delay in releasing the ENHANCE test results for its Vytorin combination drug now wants information on the company's marketing practices. The results of the ENHANCE tests, which were completed in April 2006, were only released in January 2008. The results sho... - ENHANCE Test Results Show Zetia Does Not Reduce Artery Plaque
Jan-17-08 Dallas, TX: After a two-year delay, Merck/Schering-Plough Pharmaceuticals has released the ENHANCE test results for its controversial Vytorin combination drug. Vytorin combines Merck/Schering's Zetia and the statin drug Zocor (generic simvastatin). The tests showed that Vytorin performs no better than simvastatin alone in reducing plaque buildup in the a... - More Controversy Surrounding Zetia
Jan-13-08 New York, NY: When the makers of Zetia announced that they were changing the goals of a clinical trial of the drug, after the trial had already been started, the companies faced a great deal of criticism. According to an article in Forbes, the situation was actually more controversial than that. The reason is that, according to Forbes, when the comp...